Vicarious Surgical Inc. (RBOT) Reports Q3 Loss of $0.09; Reports Cash and Cash Equivalents of $185M

Go back to Vicarious Surgical Inc. (RBOT) Reports Q3 Loss of $0.09; Reports Cash and Cash Equivalents of $185M

Canaccord Genuity Starts Vicarious Surgical inc. (RBOT) at Buy

November 5, 2021 7:09 AM EDT

Canaccord Genuity analyst Kyle Rose initiates coverage on Vicarious Surgical inc. (NYSE: RBOT) with a Buy rating and a price target of $15.00.


For an analyst ratings summary and ratings history on Vicarious Surgical inc.... More